脂质体多柔比星对初治多发性骨髓瘤疗效及安全性评估

目的：旨在分析脂质体多柔比星替代传统蒽环类药物多柔比星治疗多发性骨髓瘤（ MM）患者的有效率及安全性。方法收集2011年9月—2014年1月，共计45例初治MM患者，其中22例接受DVDT方案化疗（脂质体多柔比星20 mg· m－2· dL－1、长春新碱2 mg· d－1、地塞米松40 mg· d1－1～4、沙利度胺100 mg· d1－1－28），23例接受VADT方案化疗（多柔比星10 mg· d1－1～4、长春新碱0．5 mg· d1－1～4、地塞米松40 mg· d1－1～4、沙利度胺100 mg· d1～28）；并对患者进行跟踪随访至2014年3月；评估分析化疗有效率及副反应。结果 DVDT组和VADT组的总体有效率相似（81．8％比73．8％，P＝0．780），DVDT组骨髓抑制及心脏毒副反应较VADT组低，耐受性较好。结论脂质体多柔比星用于初治多发性骨髓瘤患者治疗的有效率和安全性均较好，适合免疫力低下且伴心脏功能不全的MM患者。

Efficacy and safety of pegylated liposomal doxorubicin in the treatment of newly diagnosed multiple myeloma

Objective To analyze the efficacy and safety of the treatment for traditional anthracycline doxorubicin replacement by pegy-lated liposomal doxorubicin in multiple myeloma ( MM) patients.Methods A total of 45 patients with newly diagnosed MM were col-lected from September 2011 to January 2014.Twenty-two cases accepted chemotherapy of DVDT ( pegylated liposomal doxorubicin 20 mg· m-2· dL-1,vincristine 2 mg· dL-1,dexamethasone 40 mg/d1 ~4,thalidomide 100 mg/d1~28),while the other 23 cases ac-cepted chemotherapy of VADT (doxorubicin 10 mg/d1~4,vincristine 0.5 mg/d1~4,dexamethasone 40 mg/d1~4,thalidomide 100 mg/d1-28);and the patients were followed up until March 2014.Then the efficacy and safety of the treatment were analyzed and as-sessed.Results The overall efficacies in DVDT and VADT group were similar (81.8%vs 73.8%,P =0.780).Adverse reactions in DVDT group were milder and more tolerate.Conclusions Pegylated liposomal doxorubicin is more efficient and safer than tradition-al doxorubicin for newly diagnosed multiple myeloma patients,especially for MM patients with low immunity and cardiac dysfunction.